Ricciuto, A., Liu, K., El‐Matary, W., Amin, M., Amir, A. Z., Aumar, M., Auth, M., Di Guglielmo, M. D., Druve Tavares Fagundes, E., Rodrigues Ferreira, A., Furuya, K. N., Gupta, N., Guthery, S., Horslen, S. P., Jensen, K., Kamath, B. M., Kerkar, N., Koot, B. G. P., … Laborda, T. J. (2024). Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium. Alimentary Pharmacology & Therapeutics, 59(10), 1236–1247. Portico. https://doi.org/10.1111/apt.17936

Shen, B., Yao, Q., & Scherl, E. J. (2024). Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients With Ileal Pouches: A Systematic Review. Diseases of the Colon & Rectum, 67(S1), S106–S114. https://doi.org/10.1097/dcr.0000000000003231

Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., Tabibian, J. H., & Assis, D. N. (2023). Reply: Insurance should cover vancomycin for primary sclerosing cholangitis. Hepatology, 77(6), E176–E177. https://doi.org/10.1097/hep.0000000000000305

Bowlus, C. L., Arrivé, L., Bergquist, A., Deneau, M., Forman, L., Ilyas, S. I., Lunsford, K. E., Martinez, M., Sapisochin, G., Shroff, R., Tabibian, J. H., & Assis, D. N. (2022). AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 77(2), 659–702. https://doi.org/10.1002/hep.32771